📊 KAPA Key Takeaways
Is Kairos Pharma, LTD. (KAPA) a Good Investment?
Kairos Pharma is a pre-revenue pharmaceutical company with significant cash burn (-$1.0M operating cash flow) and limited runway of approximately 3-4 quarters at current burn rate. With no revenue generation, negative net income of -$1.7M, and complete reliance on existing cash reserves, the company faces critical sustainability challenges without near-term commercialization or funding.
Pre-revenue biotech with a clean, debt-free balance sheet and strong current/quick ratios, but operating and net losses are widening. Cash of $4.49M against a -$3.44M operating cash outflow implies a limited runway and high likelihood of near-term dilution. Without revenue visibility or partnerships, downside risk outweighs fundamentals-based upside.
Kairos Pharma, LTD. Key Strengths (KAPA)
- Strong liquidity position with 10.31x current ratio and quick ratio
- Conservative balance sheet with zero long-term debt and 0.00x debt-to-equity ratio
- Cash reserves of $3.7M providing near-term operational runway
- Very strong liquidity (27x current/quick ratio)
- No long-term debt or interest burden
- Cash comprises a large share of assets, offering near‑term flexibility
KAPA Stock Risks: Kairos Pharma, LTD. Investment Risks
- No revenue generation; company appears to be pre-commercialization pharmaceutical venture
- Severe cash burn rate of -$1.0M per quarter with limited runway remaining
- Negative profitability: -$1.7M net income with deteriorating EPS (-30.4% YoY), resulting in -31.1% ROE and -28.8% ROA
- Zero insider buying activity in past 90 days suggests lack of management confidence
- Extremely small asset base ($5.7M total assets) with minimal operational scale
- Pre-revenue with no gross margin or line-of-sight to sales
- Worsening losses (NI -109% YoY, EPS more negative)
- Limited cash runway likely requiring dilutive capital raises
Key Metrics to Watch
- Quarterly cash burn rate and runway remaining until capital requirements
- Revenue generation milestones or commercial product launch timeline
- Clinical trial progress updates and regulatory approval status for pipeline
- Capital raising activities and partnership announcements
- Operating cash flow burn rate
- Cash & equivalents vs next-12-month operating needs
Kairos Pharma, LTD. (KAPA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.31x current ratio provides a solid financial cushion.
KAPA Profit Margin, ROE & Profitability Analysis
KAPA vs Healthcare Sector: How Kairos Pharma, LTD. Compares
How Kairos Pharma, LTD. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kairos Pharma, LTD. Stock Overvalued? KAPA Valuation Analysis 2026
Based on fundamental analysis, Kairos Pharma, LTD. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kairos Pharma, LTD. Balance Sheet: KAPA Debt, Cash & Liquidity
KAPA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kairos Pharma, LTD.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
KAPA Revenue Growth, EPS Growth & YoY Performance
Kairos Pharma, LTD. Dividends, Buybacks & Capital Allocation
KAPA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kairos Pharma, LTD. (CIK: 0001962011)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KAPA
What is the AI rating for KAPA?
Kairos Pharma, LTD. (KAPA) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KAPA's key strengths?
Claude: Strong liquidity position with 10.31x current ratio and quick ratio. Conservative balance sheet with zero long-term debt and 0.00x debt-to-equity ratio. ChatGPT: Very strong liquidity (27x current/quick ratio). No long-term debt or interest burden.
What are the risks of investing in KAPA?
Claude: No revenue generation; company appears to be pre-commercialization pharmaceutical venture. Severe cash burn rate of -$1.0M per quarter with limited runway remaining. ChatGPT: Pre-revenue with no gross margin or line-of-sight to sales. Worsening losses (NI -109% YoY, EPS more negative).
What is KAPA's revenue and growth?
Kairos Pharma, LTD. reported revenue of N/A.
Does KAPA pay dividends?
Kairos Pharma, LTD. does not currently pay dividends.
Where can I find KAPA SEC filings?
Official SEC filings for Kairos Pharma, LTD. (CIK: 0001962011) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KAPA's EPS?
Kairos Pharma, LTD. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KAPA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Kairos Pharma, LTD. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KAPA stock overvalued or undervalued?
Valuation metrics for KAPA: ROE of -31.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KAPA's AI grade for 2026?
Our dual AI analysis gives Kairos Pharma, LTD. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KAPA's free cash flow?
Kairos Pharma, LTD.'s operating cash flow is $-1.0M, with capital expenditures of N/A.
How does KAPA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -31.1% (avg: 15%), current ratio 10.31 (avg: 2).